Sudarshan Chemical Industries Ltd

Q1 FY27Chemicals & Petrochemicals

Sudarshan Chemical Industries Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹1,248

Market cap₹9.7K Cr

P/E95.9

Published13 Sept 2026

What the Q1 FY27 call signalled

1 of 3 strong

RevenueRank 3

MarginRank 3

CapexYes

Not discussed on this call: fundraise, order book.

The short version

Post Heubach acquisition, Sudarshan aims for measured revenue growth, focusing on capturing lost sales rather than aggressive expansion. Sudarshan Chemical aims for significant growth, targeting a turnover of over Rs.12,000 Crores plus in the medium term (Slide 9 referenced).

From Sudarshan Chemical Industries Ltd's Q1 FY27 earnings-call transcript · updated 13 Sept 2026.

Revenue & Sales Performance

Rank 3

Post Heubach acquisition, Sudarshan aims for measured revenue growth, focusing on capturing lost sales rather than aggressive expansion.
Current market share limits growth beyond overall market size, but there is substantial opportunity in regaining lost business.
Target to exceed Rs.12,000 Crores in topline, combining legacy and acquired businesses.
Legacy Sudarshan business expected to grow at 12-13%.
Focus on profitable growth, maintaining/growing gross margins with premium products.
Revenue CAGR of 5-7% over next 2-3 years anticipated, comprising both volume and value growth.
Confidence to grow at 2 to 2.5 times the industry growth rate due to lost business recovery and value capture initiatives.
No significant volume decline; volume growth seen despite geopolitical challenges.
No major capex required for volume growth; moderate capex for backward integration or special initiatives based on ROI.

Profitability & Margins

Sudarshan Chemical aims for significant growth, targeting a turnover of over Rs.12,000 Crores plus in the medium term (Slide 9 referenced).
Revenue CAGR is expected between 5%-7% over the next 2-3 years, with a balanced mix of volume growth and value capture (premiumization).
EBITDA is anticipated to nearly double by FY2029, with margins expected to reach or exceed double digits for the acquired business.
Value capture initiatives and cost reduction are key drivers for profitability improvement.
EPS growth is supported by operational efficiencies, revenue growth, and debt reduction efforts.
The company aspires to be debt-free while increasing EBITDA up to seven times from 2023 levels.
Management is cautious with guidance due to geopolitical uncertainties but remains confident in delivering steadfast profitability and growth.
Long-term prospects include leveraging global footprint and broad technology depth for sustainable profit expansion.

See what Sudarshan Chemical Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

No substantial new capex is expected in the near term as current capacities are sufficient for projected growth.
Moderate capex may be undertaken for special initiatives such as backward integration or product development projects, based strictly on ROI.
The company is progressing with Project Integra (One SAP) to integrate and harmonize reporting systems, expected to go live within the financial year.
Investment in setting up global capability centers and centers of excellence, aiming to boost organizational efficiency and innovation.
Continuous focus on value capture and cost reduction initiatives, which may involve capital allocation for process improvements.

Fundraising & Capital Structure

There is no explicit mention of any immediate or planned new fundraising through debt or equity in the call transcript.
The company is focused on reducing existing acquisition debt, having already prepaid a small part and plans to accelerate repayment as net debt improves.
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores.
The company aims to ultimately reach a debt-free level.
On the capex front, the company does not foresee any substantial new capital expenditure; only moderate or special projects based on ROI will be considered.
Overall, the financial strategy focuses on deleveraging and organic growth rather than new fundraising at this stage.

See what Sudarshan Chemical Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention current or expected order book or pending orders for Sudarshan Chemical Industries Limited. However, relevant insights include: - The company is confident about recovering and growing lost business from the acquired group, which suffered due to lack of focus and insolvency issues. - Supply chain continuity is maintained through sufficient safety stocks and logistics adjustments amid geopolitical uncertainties. - Customers across industries have been delaying purchases, not wanting to create stocks, indicating cautious demand. - The company sees a strong Q1 performance and anticipates growth though is adopting a wait-and-watch approach due to geopolitical factors. No specific numerical data on order book or pending orders is disclosed in the provided pages.

How does Sudarshan Chemical Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisSudarshan Chemical Industries Ltd

Rev 3Mar 3

See where Sudarshan Chemical Industries Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

Sudarshan Chemical Industries Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.8K Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Sudarshan Chemical Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…
Transpek Inds. (Q1 FY27)
Planned capex of around INR 250 crores over 5-6 years, phased. Key concall takeaways from Transpek Industry Ltd's Q1 FY27 earnings call — and how it ranks…

Compare:vs Solar Industries vs Pidilite Inds.vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Sudarshan Chemical Industries Ltd Q1 FY27 results?

What is Sudarshan Chemical Industries Ltd share price analysis?

Sudarshan Chemical Industries Ltd currently shows a below-average growth signal. The stock trades at a P/E of 95.9 with a market cap of ₹9,735 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sudarshan Chemical Industries Ltd planning capital expenditure?

No substantial new capex is expected in the near term as current capacities are sufficient for projected growth.

Keep Sudarshan Chemical Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.